Compare Tyson Foods, Inc. (TSN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tyson Foods, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Tyson Foods, Inc. trades at $52.79 (market cap $18.41B), while State Street SPDR S&P Biotech ETF trades at $154.12 (market cap $10.11B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tyson Foods, Inc. for 76 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TSN | XBI | |
|---|---|---|
Market Cap | $18.41B | $10.11B |
Volume | 3,757,599 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $68.75 | $169.55 |
52-Week Low | $50.47 | $104.99 |
Typical Hold Time | 76 Days | 37 Days |
Enterprise Value | $25.68B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $51.70, down 0.52% with mixed technical signals showing neutral overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, while Q4 2025 missed. Revenue grew to $54.44B in 2025 with thin 1.03% net margins. Analyst consensus is bullish with 53% buy ratings and $65.40 price target, though recent news highlights challenges in the beef segment and ongoing securities investigations.
The stock presents a value opportunity with low P/S (0.33) and reasonable EV/EBITDA (9.83), but faces significant execution risks from beef segment losses and margin pressure. Upside depends on successful business turnaround and resolution of legal concerns, while current price near 52-week lows offers potential for recovery if fundamentals improve.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
